SCHEMBL85767

SCHEMBL85767

COC(=O)C=C1C=C(C(C)(C)C)C(=O)C(C(C)(C)C)=C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 3/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 1/20 0.44
GPR35 Q9HC97 1/20 0.44
ALDH1A1 P00352 4/20 0.36
MAPT P10636 4/20 0.36
HPGD P15428 3/20 0.36
CES2 O00748 1/20 0.36
PKM P14618 1/20 0.36
CES1 P23141 1/20 0.36
MPI P34949 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
MCL1 Q07820 1/20 0.34
KEAP1 Q14145 1/20 0.32
NFE2L2 Q16236 1/20 0.32
HCAR2 Q8TDS4 1/20 0.32
TSHR P16473 2/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4457743 0.81 KMT2A (0.38) ATMKMT2ANPC1GPR35ALDH1A1
SCHEMBL86001 0.79 ATM (0.41) ATMKMT2ANPC1GPR35ALDH1A1
SCHEMBL4456724 0.79 ATM (0.41) ATMKMT2ANPC1GPR35ALDH1A1
SCHEMBL8144898 0.78 ATM (0.43) ATMKMT2ANPC1GPR35ALDH1A1
SCHEMBL6065230 0.78 ATM (0.36) ATMKMT2ANPC1GPR35ALDH1A1
SCHEMBL8675243 0.76 ATM (0.39) ATMKMT2ANPC1GPR35ALDH1A1
SCHEMBL20875962 0.75 ATM (0.41) ATMKMT2ANPC1GPR35ALDH1A1
SCHEMBL85970 0.73 ATM (0.49) ATMKMT2ANPC1GPR35ALDH1A1
SCHEMBL22930710 0.72 ATM (0.44) ATMKMT2ANPC1GPR35ALDH1A1
SCHEMBL15827671 0.71 ATM (0.41) ATMKMT2ANPC1GPR35ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3911687-B1 LIMONENE-BASED (METH)ACRYLATES FOR USE IN 3D PRINTING BASF SE (DE) 2023-11-01 EP disclosed
US-20230241675-A1 COMPOSITIONS, COMPRISING PLATELET-SHAPED TRANSITION METAL PARTICLES BASF SE (DE) 2023-08-03 US disclosed
US-20230241675-A1 COMPOSITIONS, COMPRISING PLATELET-SHAPED TRANSITION METAL PARTICLES BASF SE (DE) 2023-08-03 US disclosed
WO-2023072740-A1 A METHOD FOR PRODUCING INTERFERENCE ELEMENTS BASF SE (DE) 2023-05-04 WO disclosed
EP-3914458-B1 SECURITY ELEMENT BASF SE (DE) 2022-12-21 EP disclosed
US-20220220284-A1 COMPOSITIONS, COMPRISING SILVER NANOPLATELETS BASF SE (DE) 2022-07-14 US disclosed
US-20220064350-A1 LIMONENE-BASED (METH)ACRYLATES FOR USE IN 3D PRINTING BASF SE (DE) 2022-03-03 US disclosed
US-20220033678-A1 PHOTOCURABLE COMPOSITION FOR USE IN 3D PRINTING BASF SE (DE) 2022-02-03 US disclosed
US-20210402466-A1 COMPOSITIONS, COMPRISING SILVER NANOPLATELETS BASF SE (DE) 2021-12-30 US disclosed
US-20210395558-A1 UV CURABLE COMPOSITION FOR USE IN 3D PRINTING BASF SE (DE) 2021-12-23 US disclosed
US-8128804-B2 Process for stabilizing olefinically unsaturated monomers EVONIK DEGUSSA GMBH (DE) 2012-03-06 US disclosed
US-20110319535-A1 IN-CAN STABILIZERS NESVADBA PETER (CH) 2011-12-29 US disclosed
US-20110319535-A1 IN-CAN STABILIZERS NESVADBA PETER (CH) 2011-12-29 US disclosed
US-7651635-B1 Polymer inhibition of vinyl aromatic monomers using a quinone methide/alkyl hydroxylamine combination NALCO COMPANY (US) 2010-01-26 US disclosed
US-7651635-B1 Polymer inhibition of vinyl aromatic monomers using a quinone methide/alkyl hydroxylamine combination NALCO COMPANY (US) 2010-01-26 US disclosed
US-20090114878-A1 PROCESS FOR STABILIZING OLEFINICALLY UNSATURATED MONOMERS EVONIK DEGUSSA GMBH (DE) 2009-05-07 US disclosed
US-20090114878-A1 PROCESS FOR STABILIZING OLEFINICALLY UNSATURATED MONOMERS EVONIK DEGUSSA GMBH (DE) 2009-05-07 US disclosed
EP-1873199-A1 In-can stabilizers Ciba Specialty Chemicals Holding Inc. (CH) 2008-01-02 EP disclosed
US-20070225397-A1 In-Can Stabilizers CIBA SPECIALTY CHEMICALS CORP. 2007-09-27 US disclosed
US-20070225397-A1 In-Can Stabilizers CIBA SPECIALTY CHEMICALS CORP. 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220064350-A1 LIMONENE-BASED (METH)ACRYLATES FOR USE IN 3D PRINTING LIMK1, LIMA1, LIMK2 ATM 110/4885KMT2A 742/4885NPC1 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.